Mangoceuticals closed a registered direct offering on October 9, 2026, issuing 657,000 shares of common stock alongside 657,000 common warrants. The securities were sold at $0.75 per unit, generating approximately $492,750 in gross proceeds. Each warrant allows investors to purchase one additional share at an exercise price of $1.00 and expires five years from issuance. Proceeds will support working capital and general corporate purposes.
